Cat. No.
MABL-3609
Application
FACS, neutralizing, NMR, SPR, WB, ELISA, FC
Isotype
Engineer antibody
Species Reactivity
Neisseria meningitidis
Clone No.
Mab 502
From
Recombinant Antibody
Specificity
This antibody is specific for a conformational epitope located within immunodominant C‑terminal BC domain (amino acids 101‑255, fHbpC) of Neisseria meningitidis factor H binding protein (fHbp). The antigen‑binding site centers on Arg204, consisting of two β‑strand connecting loops plus a short α‑helix formed by protein folding. fHbp is a 27‑kDa membrane‑anchored lipoprotein.
Alternative Names
fHbp; fHbpC; Genome‑derived Neisseria antigen 1870; GNA 1870; Lipoprotein 2086; LP2086; Mab502
UniProt
Q9JXV4
Immunogen
The original antibody was generated by immunizing female CD1 mice with variant 1 GNA 1870 recombinant protein.
Application Notes
The original antibody (mouse IgG2a) was generated and characterized for binding specificity by Western blotting. It demonstrated bactericidal activity against Neisseria meningitidis strains MC58, M2934, and BZ83, with titers ranging from 256 to 8,192, and was successfully applied in both WB and FACS assays on strains MC58, M2934, BZ83, M4030, F6124, and BZ133. Bactericidal activity was restricted to a subset of variant 1 strains, underscoring its dependence on specific sequence conservation. Site-directed mutagenesis of recombinant GNA1870 variant 1 revealed that substituting arginine 204 with histidine abolished antibody recognition in WB, confirming Arg204 as a critical residue for binding (Giuliani et al., 2005; PMID: 15664958). Further WB analysis evaluated binding to fHbp from 10 diverse N. meningitidis strains (MC58, M4030, M01-240149, F6124, LPN17592, M01-240345, NZ98/254, M2197, M6190, and M2937). The antibody recognized fHbp in 6 strains—MC58, M4030, M01-240149, F6124, LPN17592, and M01-240345—and showed strong bactericidal activity only against MC58, suggesting strain-specific recognition driven by sequence variability. FACS confirmed surface binding to the same 6 strains, consistent with WB results. Epitope mapping by NMR using a Fab fragment revealed that the epitope does not overlap with the factor H (fH) binding site, permitting fH binding to meningococcal cells even in the presence of the antibody (Scarselli et al., 2009; PMID: 19100746). Cooperative bactericidal activity was observed when this antibody was combined with JAR 5 against strain H44/76, achieving a BC50 of <1 μg/ml. The spatial separation of its epitope at R204 and JAR 5’s at G121 (~16 Å) supports previous findings on optimal epitope spacing for synergy (Beernink et al., 2008; PMID: 18591239). SPR analysis showed the antibody has a high association rate (Ka = 1.2 µM⁻¹s⁻¹) and very low dissociation rate when binding immobilized fHbp, indicating strong and stable interaction, though Kd could not be reliably determined. The antibody does not compete with JAR 3 or JAR 5 for fHbp binding and binds live N. meningitidis strain H44/76 at concentrations ranging from 0.8 to 40 μg/ml, with binding equivalent to that of JAR 3 and JAR 5. Its binding is unaffected by physiological concentrations of human fH (~90 μg/ml). Despite robust binding, the antibody does not inhibit fH-fHbp interaction, as shown by ELISA and FACS—even at high concentrations. It activates the classical complement pathway via C1q-mediated C4b deposition but induces only limited C3b deposition, indicating weak amplification via the alternative pathway. Unlike fH-blocking antibodies such as JAR 3 and JAR 5, this antibody fails to prevent fH binding and lacks bactericidal activity in normal human serum (BC50 >100 μg/ml). In contrast, it exhibits potent bactericidal activity in fH-depleted complement (BC50 = 1.25 μg/ml), which is abolished upon reconstitution with fH (BC50 >100 μg/ml), confirming that fH interference is essential for complement-mediated killing (Giuntini et al., 2011; PMID: 21708990). Chimeric human variants of this antibody—IgG1-MAb502, IgG2-MAb502, and IgG3-MAb502—were generated and shown to bind fHbp and live N. meningitidis (strain H44/76) similarly to the original, as assessed by ELISA and flow cytometry. None inhibited fH binding. However, the IgG3-MAb502 variant, benefiting from the superior complement activation capacity of the human IgG3 isotype, demonstrated improved bactericidal activity against the wild-type strain, illustrating that bactericidal efficacy can be achieved without fH inhibition through isotype selection (Giuntini et al., 2012; PMID: 22064712).
Antibody First Published
Giuliani et al. The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies Infect Immun. 2005 Feb;73(2):1151-60. doi: 10.1128/IAI.73.2.1151-1160.2005. PMID:15664958
Note on publication
The original publication investigates the antigenic and immunogenic properties of the Neisseria meningitidis surface protein GNA 1870 and identifies the BC domain—particularly the region spanning amino acids 100 to 255—as the key target of bactericidal antibodies.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.


